Columbus Macro LLC Purchases 61,481 Shares of Kenvue Inc. (NYSE:KVUE)

Columbus Macro LLC raised its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 27.5% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 285,069 shares of the company's stock after purchasing an additional 61,481 shares during the quarter. Columbus Macro LLC's holdings in Kenvue were worth $6,836,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its stake in shares of Kenvue by 3.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after acquiring an additional 8,211,748 shares during the period. Vanguard Group Inc. grew its stake in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after acquiring an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares during the period. Geode Capital Management LLC grew its stake in shares of Kenvue by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after acquiring an additional 1,391,854 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.44 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The company has a market capitalization of $41.14 billion, a P/E ratio of 40.46, a P/E/G ratio of 2.62 and a beta of 0.98. The firm's 50 day simple moving average is $23.03 and its two-hundred day simple moving average is $22.49.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The company's revenue for the quarter was down 3.9% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.82%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on KVUE. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Citigroup boosted their target price on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Finally, Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.